Anti-amyloid-β disease-modifying therapies for Alzheimer′s disease: the dawn of a new era / 中华神经科杂志
Chinese Journal of Neurology
; (12): 959-964, 2023.
Article
in Zh
| WPRIM
| ID: wpr-994921
Responsible library:
WPRO
ABSTRACT
Alzheimer′s disease (AD) is the most common neurodegenerative disease. Its etiology and pathogenesis remain unclear. Since its inception, the amyloid-β (Aβ) cascade hypothesis has dominated the field of AD research and has provided the intellectual framework for disease-modifying therapies. Nowadays, many Aβ-targeted therapies have been accelerated approval or received Food and Drug Administration′s breakthrough therapy designation which offers a new dawn for disease-modifying treating AD. This article reviews the research progress of clinical trials of Aβ-targeting modification therapies, and summarizes the lessons learned from the clinical failure with several classes of anti-Aβ drugs. Although many challenges remain, anti-Aβ therapies have become a promising treatment strategy for AD.
Full text:
1
Index:
WPRIM
Language:
Zh
Journal:
Chinese Journal of Neurology
Year:
2023
Type:
Article